Research Topics
Species | Soonmyung PaikSummaryAffiliation: National Surgical Adjuvant Breast and Bowel Project Country: USA Publications
| Collaborators
|
Detail Information
Publications
Molecular assays to predict prognosis of breast cancerSoonmyung Paik
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
Clin Adv Hematol Oncol 5:681-2. 2007- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerSoonmyung Paik
Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
J Clin Oncol 24:3726-34. 2006..The relationship between the RS and chemotherapy benefit is not known... - HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15S Paik
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Allegheny General Hospital, Pittsburgh, PA 15212 5234, USA
J Natl Cancer Inst 92:1991-8. 2000..We hypothesized that AC would be superior to CMF only in the HER2-positive patients... - Molecular profiling of breast cancerSoonmyung Paik
Division of Disease, NSABP Foundation, Pittsburgh, Pennsylvania 15212, USA
Curr Opin Obstet Gynecol 18:59-63. 2006..This review is a comprehensive survey of molecular-profiling literature published since 2004... 
Is gene array testing to be considered routine now?Soonmyung Paik
NSAB Foundation, Pittsburgh, USA, and Samsung Cancer Research Institute, Seoul, South Korea
Breast 20:S87-91. 2011..Evidence for their clinical utility was reviewed to determine whether any of them should be considered as routine clinical test...- Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experienceSoonmyung Paik
National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
J Natl Cancer Inst 94:852-4. 2002..This report provides a snapshot of the quality of HER2 assays performed in laboratories nationwide... - Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapySoonmyung Paik
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project Foundation, Four Allegheny Center 5th Floor, East Commons Professional Building, Pittsburgh, PA 15212, USA
Clin Cancer Res 12:1019s-1023s. 2006..Recent developments in gene expression profiling technologies are discussed with their implications in clinical management of endocrine receptor-positive breast cancer... - Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancerSoonmyung Paik
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
Nat Clin Pract Oncol 2:246-54. 2005..For older samples, real-time reverse transcription-polymerase chain reaction is the method of choice for gene-expression profiling... - Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifenSoonmyung Paik
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania 15206, USA
Oncologist 12:631-5. 2007..A prospective study-the Trial Assigning Individualized Options for Treatment (Rx) (TAILORx)-to examine whether chemotherapy is required for the intermediate-risk group defined by the RS is accruing in North America... - A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerSoonmyung Paik
Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
N Engl J Med 351:2817-26. 2004..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures... 
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorinMICHAEL J O'CONNELL
National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh, Pittsburgh, PA 15212, USA
J Clin Oncol 28:3937-44. 2010....- Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Priya Rastogi
University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
J Clin Oncol 26:778-85. 2008..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS... - Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Gong Tang
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, and Pathology Division, Pittsburgh, PA, USA
Breast Cancer Res Treat 127:133-42. 2011..219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit... - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
N Engl J Med 353:1673-84. 2005..CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.).. - Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24D Craig Allred
National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
J Clin Oncol 30:1268-73. 2012..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen... - Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim
National Surgical Adjuvant Breast and Bowel Project, Division of Pathology, 1307 Federal St, Pittsburgh, PA 15212, USA
J Clin Oncol 29:4160-7. 2011..We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors... - Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or lessBernard Fisher
National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
J Clin Oncol 20:4141-9. 2002.... - The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel ProjectD Lawrence Wickerham
NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
Semin Oncol 35:522-9. 2008.... - erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancerS Paik
National Surgical Adjuvant Breast and Bowel Project, Department of Human Oncology, Allegheny University of Health Sciences, Pittsburgh, PA 15212 5234, USA
J Natl Cancer Inst 90:1361-70. 1998..Overexpression of the erbB-2 protein by breast cancer cells has been suggested to be a predictor of response to doxorubicin. A retrospective study was designed to test this hypothesis... - Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin
National Surgical Adjuvant Breast and Bowel Project, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15212, USA
Clin Cancer Res 18:6531-41. 2012..The purpose of this study was to examine the prognostic and oxaliplatin predictive value of mismatch repair (MMR) status and common hot spot mutations, which we previously identified in stage II and III colon cancer... - Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27Harry D Bear
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
J Clin Oncol 24:2019-27. 2006..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)... - Lower-category benign breast disease and the risk of invasive breast cancerJiping Wang
Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Natl Cancer Inst 96:616-20. 2004..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)... - Gene-expression-based prognostic assays for breast cancerChungyeul Kim
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
Nat Rev Clin Oncol 7:340-7. 2010.... - Clinical trial methods to discover and validate predictive markers for treatment response in cancerSoonmyung Paik
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
Biotechnol Annu Rev 9:259-67. 2003..In this paper, design strategies for clinical trials aimed at disclosing predictive markers are discussed... - Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologistsChungyeul Kim
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, Pennsylvania, USA
Arch Pathol Lab Med 133:855-9. 2009..Gene expression-based prognostic assays for breast cancer are now available as commercial reference laboratory tests covered by insurance... - Genomics of adjuvant therapy for breast cancerSeong Rim Kim
Division of Pathology, National Surgical Breast and Bowel Project Foundation, Pittsburgh, PA, USA
Cancer J 17:500-4. 2011..Postneoadjuvant setting can be then used for patients with gross residual disease to test novel therapeutic agents... - A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodesDebora Fumagalli
Department of Pathology, National Surgical Adjuvant Breast and Bowel Project, 1307 Federal St, Pittsburgh, PA 15212, USA
BMC Cancer 10:101. 2010..Our goal was to develop a high throughput, cost-effective and simple methodology for the detection of clinically relevant hot spot mutations in colon cancer... - Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacyJames Dignam
Department of Biostatistics, University of Chicago, IL, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
Methods Mol Biol 184:169-89. 2002 - HER-2 and choice of adjuvant chemotherapy in breast cancerS Paik
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
Semin Oncol 28:332-5. 2001..This article provides a critical review of the studies that offer evidence for the role of HER-2 as a predictor of response to chemotherapy... - HER2 status and benefit from adjuvant trastuzumab in breast cancerSoonmyung Paik
N Engl J Med 358:1409-11. 2008 - Effects of tamoxifen on benign breast disease in women at high risk for breast cancerElizabeth Tan-Chiu
Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
J Natl Cancer Inst 95:302-7. 2003..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women... - NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-frEleftherios P Mamounas
Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
Clin Breast Cancer 7:416-21. 2006 - Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancerNicole J McCarthy
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
Clin Cancer Res 8:3857-62. 2002..02; Bonferroni test). CONCLUSIONS: These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype... - An ideal prognostic test for estrogen receptor-positive breast cancer?Soonmyung Paik
J Clin Oncol 26:4058-9. 2008 - Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupJohn T Hamm
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Philadelphia, PA, USA
Clin Breast Cancer 8:257-63. 2008..This trial also evaluated the feasibility of tissue collection for gene-expression profiling... - Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statementSteven E Come
Breast Cancer Program, Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Clin Cancer Res 12:997s-1000s. 2006 - New generation of molecular prognostic and predictive tests for breast cancerLajos Pusztai
Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230 1439, USA
Semin Oncol 34:S10-6. 2007.... - Gene expression profiling of breast cancer: a new tumor markerSoonmyung Paik
Breast Oncology Program, University of Michigan Health System, 1500 E. Medical Center Dr, CCGC 6203, Ann Arbor, MI 48109-0942, USA
J Clin Oncol 23:1631-5. 2005 - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerAntonio C Wolff
American Society of Clinical Oncology, Alexandria, VA, USA
J Clin Oncol 25:118-45. 2007..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker... - Anthracyclines in the treatment of HER2-negative breast cancerSoonmyung Paik
J Natl Cancer Inst 100:2-4. 2008 - Development of the 21-gene assay and its application in clinical practice and clinical trialsJoseph A Sparano
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
J Clin Oncol 26:721-8. 2008.... - HER2 testing in breast cancer: NCCN Task Force report and recommendationsRobert W Carlson
Stanford Hospital and Clinics
J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed... - Research issues affecting preoperative systemic therapy for operable breast cancerAntonio C Wolff
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 189, Baltimore, MD 21231 1000, USA
J Clin Oncol 26:806-13. 2008..PST requires an experienced and cohesive multidisciplinary team for it to fulfill its potential in both research and clinical care... - Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridizationRalf T Henke
Lombardi Cancer Center, Georgetown University, Washington, DC, USA
Methods 38:253-62. 2006..We conclude that ISH is a reliable and cost effective approach to gene expression analysis in archival tissues that is amenable to screening of series of tissues or of genes of interest... - Predictive value of microsatellite instability-high remains controversialGeorge P Kim
J Clin Oncol 25:4857; author reply 4857-8. 2007 - Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative StudyGeorge P Kim
National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Mayo Clinic, Jacksonville, FL 32224, USA
J Clin Oncol 25:767-72. 2007..The role of high-degree microsatellite instability (MSI-H) as a marker to predict benefit from adjuvant chemotherapy remains unclear...